Abstract 460P
Background
Cancer diagnosis and treatment can give rise to psychological challenges for patients. Amidst the adversity, there exists the potential for post-traumatic growth (PTG), a phenomenon characterized by positive psychological changes and personal development following traumatic experiences. Group-based interventions have emerged as a promising avenue for fostering PTG among individuals with cancer. This systematic review aims to assess the group-based interventions designed to facilitate PTG in cancer patients.
Methods
A comprehensive search was conducted among PubMed, EMBASE, Science Direct, and Scopus. Keywords used were group-based intervention, group therapy, PTG, positive psychological change, and cancer. Publications were limited to English manuscripts published in the last 10 years. Quality of each studies were assessed with Newcastle-Ottawa Scale (NOS).
Results
This review encompassed a selection of 12 studies, with 970 individuals aged above 18 years. The sampled patients displayed wide cancer types, including breast, gynaecologic, hematologic, head and neck, gastrointestinal, urological, and lymphoma. Group therapies in this review were mindfulness-based psychotherapy, cognitive behavioural stress management, acceptance and commitment therapy, supportive and positive group therapy, art and relaxation response resiliency mind-body program, varied from 5-12 sessions. The primary assessment tool is Post-Traumatic Growth Inventory (PTGI). The findings suggest that group interventions contribute to the personal strength, positive affect, and sense of meaning in cancer-related trauma. While positive trends were observed, the magnitude of PTG outcomes varied, likely influenced by duration, composition, and participant readiness for growth.
Conclusions
To conclude, this systematic review assesses the potential of group-based interventions as resource in promoting PTG among cancer patients. Nevertheless, the variations in outcomes across studies emphasize the need for interventions, accounting for individual differences. This review contributes to our understanding of the relationship between group-based interventions and PTG among cancer patients, paving the way for further research.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
D. G. William.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract